# Phase III Study of ASP2151 in Herpes Simplex Patients

> **NCT01959295** · PHASE3 · COMPLETED · sponsor: **Maruho Co., Ltd.** · enrollment: 468 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **DRUG:** ASP2151
- **DRUG:** ASP2151 placebo

## Key facts

- **NCT ID:** NCT01959295
- **Lead sponsor:** Maruho Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-04-27
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959295, "Phase III Study of ASP2151 in Herpes Simplex Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01959295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*